Trusted Resource for Clinical Trials, Protocols & Progress
Approval of a new drug is just the beginning of its lifecycle. In many cases, further data collected during Phase 4 clinical trials provides the evidence needed to expand a product’s use into new indications, broader populations, or alternative dosages. These expansions often respond to clinical demand, real-world use trends, or evolving therapeutic understanding.
Click to read the full article.
While early-phase clinical trials typically involve healthy adult volunteers, Phase 1 studies sometimes need to assess how drugs behave in special populations, including the elderly, patients with renal impairment, and those with hepatic dysfunction. These subgroups are often underrepresented in clinical research, yet they represent a significant portion of real-world drug users. Studying pharmacokinetics (PK), safety, and tolerability in these groups ensures optimal dosing and informs labeling for safe use. This article explores the rationale, design, and regulatory framework for including special populations in Phase 1 trials.
Click to read the full article.
In drug development, especially during Phase 2 clinical trials, time and precision are crucial. One way to accelerate development and assess early drug efficacy is through the use of surrogate endpoints. These are indirect measures that substitute for clinical outcomes. Surrogate endpoints can dramatically reduce trial duration and cost, but their use comes with significant scrutiny from regulators. This tutorial explores what surrogate endpoints are, when they are used, and how regulatory authorities evaluate them for clinical and marketing decisions.
Click to read the full article.
Patient retention in Phase 3 trials is just as important as recruitment. A dropout can lead to incomplete data, reduced statistical power, increased costs, and protocol deviations. Since Phase 3 trials are long-term, involve complex procedures, and span multiple visits, keeping patients engaged is critical for trial success and regulatory submission.
Click to read the full article.
Once a drug is approved and enters the market, real-world data (RWD) becomes central to understanding its long-term safety, effectiveness, and use in diverse patient populations. Among the richest sources of RWD are Electronic Health Records (EHRs) and claims data—digital footprints of everyday medical care, covering prescriptions, diagnoses, procedures, and health outcomes.
Click to read the full article.
Drug-drug interactions (DDIs) represent a major challenge in clinical pharmacology, especially during the early development phase. In Phase 1 trials, understanding how a new investigational product (IP) behaves when co-administered with other commonly used medications is crucial for patient safety and dose optimization. DDI studies identify whether a drug is a perpetrator (causing an interaction) or a victim (affected by another drug). This tutorial outlines the essential components of DDI study design in Phase 1, including regulatory guidance, PK/PD endpoints, selection of probe substrates, and data interpretation.
Click to read the full article.
While Phase 2 trials traditionally focus on efficacy and dose optimization in adult patients, modern regulatory science increasingly demands evaluation in special populations early in the drug development process. These include vulnerable groups such as elderly patients, pediatric populations, and individuals with renal or hepatic impairment. Designing Phase 2 studies for these populations requires specialized considerations to ensure safety, dosing accuracy, and clinical relevance.
Click to read the full article.
Data lock (also called “database lock”) is the formal, irreversible process of closing the clinical database for statistical analysis after all trial data has been reviewed, cleaned, and finalized. In Phase 3 trials, where regulatory submissions rely on the final dataset, data lock marks a major milestone that signals the trial has moved from execution to analysis.
Click to read the full article.
The explosion of social media and digital patient communities has revolutionized how people share health experiences. In the post-marketing landscape, these platforms have emerged as valuable sources of real-time safety signals for drugs and medical products. Phase 4 clinical trials are increasingly incorporating social media monitoring as part of a proactive pharmacovigilance strategy, supplementing traditional adverse event reporting systems and expanding the net for early detection of adverse drug reactions (ADRs).
Click to read the full article.
Phase 1 clinical trials in oncology differ significantly from those in other therapeutic areas. Unlike traditional Phase 1 studies conducted in healthy volunteers, oncology trials are usually initiated directly in patients with advanced cancers. These trials aim not only to assess safety and pharmacokinetics (PK), but also to explore early signs of efficacy, dose-response, and biomarker correlations. With the rise of immunotherapies, targeted agents, and biologics, designing and executing early-phase oncology trials has become more complex and strategically critical to success in later phases.
Click to read the full article.
